These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 23155289)

  • 1. An immunoassay method for the pharmacokinetics of 5-fluorouracil in patients with gastric cancer administered adjuvant chemotherapy.
    Matsumoto H; Higashida M; Kubota H; Murakami H; Tsutsumi K; Nakashima H; Oka Y; Okumura H; Nakamura M; Hirai T
    Anticancer Res; 2012 Nov; 32(11):5111-4. PubMed ID: 23155289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of 5-FU plasma concentration by 13C breath test in patients treated with oral 5-FU analogs.
    Higashida M; Matsumoto H; Kubota H; Murakami H; Kawabe Y; Nakashima H; Oka Y; Okumura H; Nakamura M; Hirai T
    Anticancer Res; 2012 Dec; 32(12):5407-14. PubMed ID: 23225444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of gastrectomy on the pharmacokinetics of S-1, an oral fluoropyrimidine, in resectable gastric cancer patients.
    Kochi M; Fujii M; Kanamori N; Kaiga T; Aizaki K; Takahashi T; Takayama T
    Cancer Chemother Pharmacol; 2007 Oct; 60(5):693-701. PubMed ID: 17690883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacokinetics of 5-FU after S-1 oral administration for adjuvant chemotherapy in gastric cancer patients].
    Matsumoto H; Hirai T; Hirabayashi Y; Murakami H; Higashida M; Kawabe Y; Fuchimoto M; Fujikura H; Hato S; Urakami A; Yamashita K; Tsunoda T
    Gan To Kagaku Ryoho; 2007 Jun; 34(6):869-73. PubMed ID: 17565248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of gastrectomy on the pharmacokinetics of 5-fluorouracil and gimeracil after oral administration of S-1.
    Tsuruoka Y; Kamano T; Kitajima M; Kawai K; Watabe S; Ochiai T; Sakamoto K; Shirasaka T
    Anticancer Drugs; 2006 Apr; 17(4):393-9. PubMed ID: 16549996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil].
    Yamada Y
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():37-41. PubMed ID: 16897970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
    Peters GJ; Noordhuis P; Van Kuilenburg AB; Schornagel JH; Gall H; Turner SL; Swart MS; Voorn D; Van Gennip AH; Wanders J; Holwerda U; Smid K; Giaccone G; Fumoleau P; Van Groeningen CJ
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):1-12. PubMed ID: 12739060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of dimethylnitrosamine-induced liver dysfunction on the pharmacokinetics of 5-fluorouracil after administration of S-1, an antitumour drug, to rats.
    Yoshisue K; Kanie S; Nishimura T; Chikamoto J; Nagayama S
    J Pharm Pharmacol; 2009 Dec; 61(12):1643-51. PubMed ID: 19958587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug.
    Hirata K; Horikoshi N; Aiba K; Okazaki M; Denno R; Sasaki K; Nakano Y; Ishizuka H; Yamada Y; Uno S; Taguchi T; Shirasaka T
    Clin Cancer Res; 1999 Aug; 5(8):2000-5. PubMed ID: 10473078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of S-1, a novel oral fluorouracil antitumor drug, for a chronic renal failure patient maintained on hemodialysis.
    Tominaga K; Higuchi K; Okazaki H; Suto R; Hamaguchi M; Tanigawa T; Sasaki E; Shiba M; Watanabe T; Fujiwara Y; Oshitani N; Matsumoto T; Arakawa T
    Oncology; 2004; 66(5):358-64. PubMed ID: 15331922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [TS-1 treatment for progressive gastric cancer in a patient on chronic dialysis--assessment of dosage regimen by monitoring blood concentrations of therapeutic drugs (TDM)].
    Tanaka T; Fujita S; Tanaka N; Ooka M; Okajima S; Tanaka N
    Gan To Kagaku Ryoho; 2005 Jun; 32(6):841-5. PubMed ID: 15984528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and utilization of a combined LC-UV and LC-MS/MS method for the simultaneous analysis of tegafur and 5-fluorouracil in human plasma to support a phase I clinical study of oral UFT®/leucovorin.
    Peer CJ; McManus TJ; Hurwitz HI; Petros WP
    J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Jun; 898():32-7. PubMed ID: 22565063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacokinetics and adverse event of TS-1 administered through gastrostomy].
    Hirano K; Nakamura K; Hasegawa M
    Gan To Kagaku Ryoho; 2005 Jun; 32(6):859-62. PubMed ID: 15984532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function.
    Ikeda M; Furukawa H; Imamura H; Shimizu J; Ishida H; Masutani S; Tatsuta M; Kawasaki T; Satomi T
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):25-32. PubMed ID: 12111108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, efficacy and pharmacokinetics of S-1 in a hemodialysis patient with advanced gastric cancer.
    Tomiyama N; Hidaka M; Hidaka H; Kawano Y; Hanada N; Kawaguchi H; Arimori K; Nakamura C
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):807-9. PubMed ID: 20037758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
    Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
    Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of S-1 in patients with peritoneal dissemination of gastric cancer.
    Oshima T; Yamada R; Hatori S; Kunisaki C; Imada T
    Oncol Rep; 2006 Aug; 16(2):361-6. PubMed ID: 16820916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
    Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
    Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternative pharmacokinetics of S-1 components, 5-fluorouracil, dihydrofluorouracil and alpha-fluoro-beta-alanine after oral administration of S-1 following total gastrectomy.
    Kim WY; Nakata B; Hirakawa K
    Cancer Sci; 2007 Oct; 98(10):1604-8. PubMed ID: 17683513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A case of postoperative gastric cancer responding to adjuvant chemotherapy with TS-1--a novel oral formation of 5-fluorouracil].
    Yamada T; Morishita M; Yoshida K; Kinoshita S; Yokoi K; Nakamura M; Morita K; Harada T; Yagi S; Kitagawa S; Nakagawa M
    Gan To Kagaku Ryoho; 2001 Nov; 28(12):1909-12. PubMed ID: 11729486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.